Drugs / BGB-DXP593
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT04669262 | Dec 2020 → May 2021 | — | BeiGene | Completed | No outcome recorded |
| Phase 1 | NCT04532294 | Sep 2020 → Feb 2021 | COVID-19 | BeiGene | Completed | No outcome recorded |
| Phase 21 trial · 1 missed | ||||||
| Phase 2 | NCT04551898 | Dec 2020 → May 2021 | COVID-19 | BeiGene | Completed | Missed primary |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BGB DXP593 | “A First-in-Human, Randomized, Double-Blind, Placebo Controlled, Single Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of...” NCT04532294 ↗ |
| Action | Inhibit | “BGB-DXP593, a neutralising monoclonal antibody against SARS-CoV-2, has demonstrated strong activity in reducing viral RNA copy number” PMID 36820098 ↗ Feb 2023 |
| Modality | Monoclonal antibody | “BGB-DXP593, a neutralising monoclonal antibody against SARS-CoV-2” PMID 36820098 ↗ Feb 2023 |
| Route | Intravenous | “Administered intravenously (IV) as specified in the treatment arm” NCT04532294 ↗ |